As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Silexion Therapeutics Corp. The largest reported stake is Moringa Sponsor, LP's, at 17.7%. 15 filings are on record since September 15, 2025 (Schedule 13D/A, September 28, 2026).
Sell to companies like Silexion Therapeutics Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Moringa Sponsor, LP · Sole voting: 1,954,056 · Shared voting: 0 · Sole dispositive: 1,954,056 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-09-28
- · Holder: Moringa Sponsor, LP · Percent: 25% · SCHEDULE 13D/A
- · Reporting person: Mitchell P. Kopin · Sole voting: 0 · Shared voting: 286,866 · Sole dispositive: 0 · Shared dispositive: 273,866 · SCHEDULE 13G, 2026-08-18
- · Holder: Mitchell P. Kopin · Percent: 0% · SCHEDULE 13G/A
- · Holder: Moringa Sponsor, LP · Percent: 10.6% · SCHEDULE 13D/A
Silexion Therapeutics Corp has 15 Schedule 13D or 13G filings on record since 2025-09-15. 2 holders' latest filing reports 5% or more of ordinary shares, par value $0.0135 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Moringa Sponsor, LP | 17.7% | 1,954,056 | SCHEDULE 13D/A, 2026-09-28 | 2026-09-18 |
| Lincoln Alternative Strategies LLC | 6.18% | 131,250 | SCHEDULE 13G, 2025-09-15 | 2025-09-12 |
| 4.99% | 286,866 | SCHEDULE 13G, 2026-08-18 | 2026-08-11 | |
| Lind Global Fund III LP | 4.96% | 212,500 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| Orca Capital AG | 4.9% | 109,432 | SCHEDULE 13G/A, 2025-09-15 | 2025-09-11 |
Holding shares or following this stake? See who's behind Silexion Therapeutics Corp and the warning signs.
Free to see. No signup.
Keep reading
More on Silexion Therapeutics Corp and the records around it.
Silexion Therapeutics Corp elsewhere on the record
- IPO filing Aug 2026
- Form D filing Aug 2025
- Who owns it
Companies that share a holder
- Lind Global Fund III LP also filed stake reports on 11 other companies: Dare Bioscience, Inc. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026), Enveric Biosciences, Inc. (Aug 2026)
- Lincoln Alternative Strategies LLC also filed stake reports on 13 other companies: Celularity Inc (Feb 2026), Jaguar Health, Inc. (Feb 2026), Longeveron Inc. (Feb 2026)
- Orca Capital AG also filed stake reports on 19 other companies: DarkIris Inc. (Oct 2026), Neo-Concept International Group Holdings Limited (Oct 2026), NFT Limited (Sep 2026)
Watch Silexion Therapeutics Corp
Get an email when Silexion Therapeutics Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Silexion Therapeutics Corp?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Silexion Therapeutics Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Silexion Therapeutics Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
27 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Moringa Sponsor, LP | 1,954,056 | 0 | 1,954,056 | 0 | SCHEDULE 13D/A, 2026-09-28 |
| Moringa Partners Ltd | 0 | 1,954,056 | 0 | 1,954,056 | SCHEDULE 13D/A, 2026-09-28 |
| Ilan Levin | 0 | 1,954,056 | 0 | 1,954,056 | SCHEDULE 13D/A, 2026-09-28 |
| Mitchell P. Kopin | 0 | 286,866 | 0 | 273,866 | SCHEDULE 13G, 2026-08-18 |
| Daniel B. Asher | 0 | 286,866 | 0 | 273,866 | SCHEDULE 13G, 2026-08-18 |
| Intracoastal Capital LLC | 0 | 286,866 | 0 | 273,866 | SCHEDULE 13G, 2026-08-18 |
The latest filing identifies Silexion Therapeutics Corp by CUSIP G1281K130 and gives its principal executive office as 12 Abba Hillel Road, Ramat Gan (SCHEDULE 13D/A, 2026-09-28).
Source of funds (Item 3)
On September 15, 2025, Silexion Therapeutics Corp, a Cayman Islands exempted company ("Silexion" or the "Issuer") issued 45,000 ordinary shares, par value $0.0135 per share, of Silexion, to Moringa Sponsor, LP (the "Sponsor") upon conversion by Silexion of an aggregate of $1.8 million of the outstanding amount under the Amended and Restated Promissory Note, dated August 15, 2024, in an original principal amount of $3.4 million, issued by Silexion to the Sponsor.Moringa Sponsor, LP, SCHEDULE 13D/A, 2026-09-28
Purpose of Transaction (Item 4)
Moringa Sponsor, LP
The information contained in Item 3 is incorporated by reference in its entirety into this Item 4. On June 22, 2026, Moringa Sponsor, LP filed a claim against Silexion Therapeutics Corp and two of its senior officers (the "Claim"), alleging deliberate and systematic breaches of the Amended and Restated Promissory Note, dated August 15, 2024 (the "Note"). In the Claim, Moringa Sponsor, LP alleges, among other things, that Silexion breached the conditions governing conversion of indebtedness under the Note, including by failing to use the correct share price for conversions, failing to provide the required prior notice, effecting conversions below the minimum amount, and failing to deliver the shares within the required timeframe. Moringa Sponsor, LP seeks a declaration that the purported conversions are void, a determination that an Event of Default has occurred entitling it to immediate repayment of the entire outstanding debt, and, in the alternative, an order correcting the conversions and awarding damages.Item 4 of the SCHEDULE 13D/A filed 2026-09-28
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-15 | Lincoln Alternative Strategies LLC | 6.18% | SCHEDULE 13G |
| 2025-09-15 | Orca Capital AG | 6.2% | SCHEDULE 13G |
| 2025-09-15 | Orca Capital AG | 4.9% | SCHEDULE 13G/A |
| 2025-09-17 | Mitchell P. Kopin | 9.99% | SCHEDULE 13G |
| 2025-09-18 | Lind Global Fund III LP | 9.9% | SCHEDULE 13G |
| 2025-09-23 | Moringa Sponsor, LP | 14.67% | SCHEDULE 13D/A |
| 2025-11-14 | Lind Global Fund III LP | 6.4% | SCHEDULE 13G/A |
| 2026-02-13 | Mitchell P. Kopin | 9.4% | SCHEDULE 13G/A |
| 2026-05-15 | Lind Global Fund III LP | 4.96% | SCHEDULE 13G/A |
| 2026-05-29 | Moringa Sponsor, LP | 32.99% | SCHEDULE 13D/A |
| 2026-06-23 | Moringa Sponsor, LP | 10.6% | SCHEDULE 13D/A |
| 2026-08-13 | Mitchell P. Kopin | 0% | SCHEDULE 13G/A |
| 2026-08-18 | Mitchell P. Kopin | 4.99% | SCHEDULE 13G |
| 2026-08-19 | Moringa Sponsor, LP | 25% | SCHEDULE 13D/A |
| 2026-09-28 | Moringa Sponsor, LP | 17.7% | SCHEDULE 13D/A |
Questions about who owns Silexion Therapeutics Corp
Who owns Silexion Therapeutics Corp?
On this page, 2 holders' latest ownership filings report 5% or more of Silexion Therapeutics Corp: Moringa Sponsor, LP (17.7%, Schedule 13D/A, filed 2026-09-28) and Lincoln Alternative Strategies LLC (6.18%, Schedule 13G, filed 2025-09-15).
Who are the largest shareholders of Silexion Therapeutics Corp?
By the share each holder's latest filing reports, the largest holders of Silexion Therapeutics Corp on this page are Moringa Sponsor, LP (17.7%) and Lincoln Alternative Strategies LLC (6.18%).
When did Moringa Sponsor, LP buy into Silexion Therapeutics Corp?
The filings give report dates, not purchase dates. The earliest filing from Moringa Sponsor, LP on this page is the Schedule 13D/A, filed 2025-09-23, reporting 14.67%; its latest, Schedule 13D/A filed 2026-09-28, reports 17.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 15 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Silexion Therapeutics Corp
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 13, 2026 | IPO filing, Form 424B4 | — | IPO filings | Source |
| August 10, 2026 | IPO filing, Form S-1/A | — | IPO filings | Source |
| August 7, 2026 | IPO filing, Form S-1 | — | IPO filings | Source |
| July 31, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| September 12, 2025 | IPO filing, Form 424B4 | — | IPO filings | Source |
| September 5, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| August 26, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| August 11, 2025 | Form D, private offering | $3.60M sold | Form D page | Source |
| March 27, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
| February 12, 2025 | IPO filing, Form S-1 | — | IPO filings | Source |
| January 17, 2025 | IPO filing, Form 424B4 | — | IPO filings | Source |
| January 14, 2025 | IPO filing, Form S-1/A | — | IPO filings | Source |
The newest 12 of 16 records.
Tools for this story
Each opens in a new tab, filled in for Silexion Therapeutics Corp. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.